MIM
IMUX icon

MetLife Investment Management’s Immunic IMUX Stock Holding History

MetLife Investment Management’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,188
Closed -$134K – 2882
2022
Q1 		$134K Buy
+1,188
New +$138K ﹤0.01% 2557

Other funds holding IMUX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

MetLife Investment Management's IMUX Position: Q2 2022 in Review

MetLife Investment Management sold out of Immunic (IMUX) in Q2 2022, closing a stake of 1,188 shares — an estimated $134K sold.

MetLife Investment Management first reported a position in IMUX in Q1 2022 and held it in 1 quarter. The position peaked at $134K in Q1 2022. 72 funds tracked by Wall St. Rank hold IMUX as of Q2 2022.

  • MetLife Investment Management reported no remaining Immunic position as of Q2 2022 after selling out during the quarter.
  • MetLife Investment Management sold 1,188 Immunic shares in Q2 2022, an estimated $134K.
  • MetLife Investment Management first reported a position in Immunic in Q1 2022 and held it in 1 quarter.
  • MetLife Investment Management's Immunic position peaked at $134K in Q1 2022.
  • 72 funds tracked by Wall St. Rank held Immunic as of Q2 2022.

Based on MetLife Investment Management's 13F filing for Q2 2022, filed 11 Aug 2022.